Provided herein are pediatric formulations comprising 2 methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate, and methods for treating, preventing and managing cancer using the same.

A compartmented hard shell capsule for containing active formulations, and methods and apparatuses for forming, filling and encapsulating the compartmented hard shell capsules. The compartmented hard shell capsule includes a cap portion and a body portion. The cap portion has a hollow cavity defining a cap chamber. The body portion can be removably inserted into the cap portion. The body portion has an open end, a closed end and a sidewall defining a hollow cavity and a serrated edge along the open end. The serrated edge may be folded over to form a barrier to enclose the body portion, thereby creating a body chamber that is separate from the cap chamber when the body portion is inserted into the cap portion. The methods for filling and encapsulating the compartmented hard shell capsules can be completed in one continuous process, which increases cost-effectiveness for use of the compartmented hard shell capsules.

Various methods and apparatuses are presented for an ingestible capsule that includes a digital, ingestible sensor component—or ingestible sensor—embedded into the capsule. The ingestible sensor component may be configured to activate upon coming into contact with conductive fluid, such as a body's stomach fluid. Once activated, the ingestible sensor component may be configured to perform various tasks, such as transmitting one or more signals and obtaining biometric data about the body that ingested the capsule.

A solid pharmaceutical composition comprising a quinazoline derivative or a medicinal salt thereof, and a preparation method therefor. Specifically, provided is a solid pharmaceutical composition comprising N.sup.6-(1-acryloylpiperidin-4-yl)-N.sup.4-(3-chloro-4-fluorophenyl)-7-methoxyquinazoline-4,6-diamine or a medicinal salt thereof, and a preparation method therefor and use thereof.

##STR00001##

This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compounds for treating disorders requiring a modulation of certain nutrients to the body including diabetes type II and clinical obesity.

The present disclosure belongs to the technical field of soft capsules, and particularly relates to a plant soft capsule and a preparation method and application thereof. The plant soft capsule with excellent performance is prepared from carrageenan, starch, a plasticizer and water by controlling the weight-average molecular weight of the carrageenan to be 1.2×10.sup.6 to 2.0×10.sup.6. Compared with a plant soft capsule in the existing technology, the plant soft capsule of the present discourse has lower production cost, and the product quality meets the requirements of gelatin soft capsules; and on the premise of high production efficiency, a low oil leakage rate is achieved, and the rupture time meets United States Pharmacopoeia (USP) standards. The plant soft capsule prepared according to the present disclosure can be filled with an active component as a content and used for preparation of a plurality of drugs, functional food or dietary nutritional supplements.

A method for treating the gastro-intestinal or a urogenital system of a subject with prebiotic nutrients and probiotic bacteria is provided. Multi-chamber products are described which include at least two chambers wherein probiotic bacteria or human microbiome transplants are contained in one or more inner chambers and wherein prebiotic nutrients are contained in an outer chamber, the outer chamber completely enclosing the inner chamber(s). One or both chambers may contain a pharmaceutically acceptable material that is solid outside the human body when in a dry environment, but that melts at internal body temperature. The products may be administered by oral, rectal, vaginal, or urethral routes.

The invention relates to the field of medicine, specifically the field of atypical antipsychotics. New compositions are provided that provide drug solutions of high stability.

This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption from orally administered antibiotics.

The present invention provides ingestible dosage form articles such as opaque capsules with reduced light transmittance.